Just as the assessment is an important part of Psychedelic-Assisted Psychotherapy (PAP), the integration after PAP treatment is even more important.
Several key elements are involved in strategic integration in an attempt to avoid influencing or fulfilling the therapist’s agenda above what is important to the patient.
Ketamine has been used legally for depression, anxiety, and a host of other mental health conditions. This recording reviews the key elements of integration strategies specific to the mental health condition being addressed. Ketamine treatment has some specific nuances that will be outlined and compared to other psychedelics.
Ways to improve the efficacy of the integration are described with specific case examples to highlight tools to improve outcome.
Viewers will leave with an understanding as to when ketamine assisted psychotherapy might be beneficial to specific patients.
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
This online program is worth 1 hours CPD.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice (5.78 MB) | 58 Pages | Available after Purchase | |
| Manual - The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice - French (5.78 MB) | 58 Pages | Available after Purchase | |
| Text Document | Transcript - French (36.9 KB) | 13 Pages | Available after Purchase |
| Manual - The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice - Italian (5.78 MB) | 58 Pages | Available after Purchase | |
| Text Document | Transcript - Italian (36.9 KB) | 13 Pages | Available after Purchase |
Phil Wolfson, MD, is the creator of a new psychotherapy modality based on use of the medicine ketamine – Ketamine Assisted Psychotherapy (KAP). Phil is the CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Training Center - now numbering over 1000 practitioners across the US and internationally. KRF’s Ketamine Psychotherapy Associates membership organization promotes the development of KAP practices and KAP wisdom on an ongoing basis. He is the author of The Ketamine Papers and Noe – A Father/Son Song of Love, Life, Illness and Death. He has been the principal investigator of the MAPS.org Phase 2 study of MDMA treatment for individuals with life-threatening illnesses. Dr. Wolfson’s work is the result of an intense, now many decades long clinical psychiatry/psychotherapy practice. He is a founder of Progressive Therapeutics Inc, an exciting new commercial psychedelic and psychoactive drug development corporation that is allied with his non-profit. The second volume of The Ketamine Papers is being prepared for publication in 2025.
He was featured in lead articles in the New Yorker, Vanity Fair and Oprah Magazine. KRF’s research, education and training are leading in the field.
Phil Wolfson is a sixties activist, psychiatrist/psychotherapist, writer, practicing Buddhist and psychonaut who has lived in the Bay Area for 46 years. In the 1980s, he participated in clinical research with MDMA (Ecstasy). He has created 9 patents for unique herbal medicines and ketamine. Phil was a founding member of the Heffter Research Institute. He is a journalist and author of numerous articles on politics, transformation, psychedelics, consciousness and spirit.
He is a graduate of Brandeis University and NYU School of Medicine.
Speaker Disclosures:
Financial: Philip Wolfson is the founder and CEO of The Ketamine Research Foundation. He has an ownership interest in Progressive Therapeutics, Inc. Dr. Wolfson will address off-label uses. He has no relevant financial relationships with ineligible organizations.
Non-financial: Philip Wolfson has no relevant non-financial relationship to disclose.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.co.uk or call 01235847393.
Please wait ...
